Equities research analysts predict that Opko Health Inc. (NASDAQ:OPK) will report $260.62 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Opko Health’s earnings, with the highest sales estimate coming in at $269.90 million and the lowest estimate coming in at $252.30 million. Opko Health reported sales of $263.50 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 1.1%. The business is expected to issue its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Opko Health will report full year sales of $1.03 billion for the current year, with estimates ranging from $1.01 billion to $1.05 billion. For the next fiscal year, analysts forecast that the business will post sales of $1.09 billion per share, with estimates ranging from $1.03 billion to $1.13 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Opko Health.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.06. Opko Health had a negative net margin of 31.73% and a negative return on equity of 9.32%. The firm had revenue of $263.69 million during the quarter, compared to analyst estimates of $260.37 million.
OPK has been the subject of a number of analyst reports. ValuEngine raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price objective on shares of Opko Health in a report on Tuesday, May 8th. BidaskClub raised shares of Opko Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 10th. Barrington Research reaffirmed a “buy” rating and set a $7.00 target price on shares of Opko Health in a research note on Wednesday, May 9th. Finally, Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating and set a $4.75 target price for the company in a research note on Wednesday, May 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $10.95.
Shares of OPK traded down $0.08 during mid-day trading on Tuesday, reaching $5.42. The stock had a trading volume of 6,292,497 shares, compared to its average volume of 7,250,249. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.94. Opko Health has a 52-week low of $2.66 and a 52-week high of $7.24.
In related news, CEO Phillip Md Et Al Frost bought 10,000 shares of the stock in a transaction on Friday, May 25th. The stock was bought at an average price of $3.70 per share, with a total value of $37,000.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $11,355,118.70. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have acquired 562,719 shares of company stock valued at $2,541,630. 42.74% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the stock. Castleview Partners LLC purchased a new stake in shares of Opko Health during the 1st quarter worth $103,000. SG Americas Securities LLC purchased a new stake in shares of Opko Health during the 2nd quarter worth $136,000. North Star Investment Management Corp. purchased a new stake in shares of Opko Health during the 2nd quarter worth $141,000. RPg Family Wealth Advisory LLC boosted its position in shares of Opko Health by 74.3% during the 2nd quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 13,250 shares in the last quarter. Finally, Xact Kapitalforvaltning AB purchased a new stake in shares of Opko Health during the 4th quarter worth $179,000. Hedge funds and other institutional investors own 23.55% of the company’s stock.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Article: Trading Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.